HUMIRA

HUMIRA

Displaying 10 out of 9 results

  1. The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

    Merck's biosimilar to AbbVie's Humira wins FDA approval

    The U.S. Food and Drug Administration approved Merck & Co Inc's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, the ...
  2. FILE PHOTO: The Allergan logo is seen in this photo illustration in Singapore

    AbbVie looks beyond Humira with US$63 billion deal for Botox-maker Allergan

    AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than US$60 billion, the Wall Street Journal reported on Tuesday, citing ...
  3. FILE PHOTO:  A trader works by the post that trades AbbVie on the floor of the New York Stock Excha

    AbbVie's Skyrizi drug to treat psoriasis wins US approval

    AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when ...
  4. The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co

    Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

    Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription ...
  5. FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring

    FDA approves Novartis' copy of AbbVie bestseller Humira

    The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.
  6. FILE PHOTO: A screen displays the share price for pharmaceutical maker AbbVie on the floor of the N

    AbbVie settles Humira biosimilar dispute with Fresenius Kabi

    U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and ...
  7. FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

    Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

  8. New Content Item

    California insurance commissioner sues AbbVie over Humira

  9. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stoc

    Europe ready to cash in on cheap copies of AbbVie biotech drug

    U.S. drugmaker AbbVie ABBV.N faces a crunch moment in Europe in mid-October when less-expensive copies of its US$18-billion-a-year biologic drug ...